Literature DB >> 33277749

A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer.

Takaaki Masuda1, Atsushi Nonami2, Fumiaki Tanaka3, Yuki Ando1, Masatoshi Eto2, Koshi Mimori1.   

Abstract

Entities:  

Keywords:  adoptive immunotherapy; bevacizumab; breast cancer; αβ T-cell

Mesh：

Substances：

Year:  2020        PMID： 33277749      PMCID： PMC7839766          DOI： 10.1111/tbj.14108

Source DB:  PubMed          Journal:  Breast J        ISSN： 1075-122X            Impact factor:   2.431


× No keyword cloud information.
  6 in total

1.  Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.

Authors:  Fuminori Ishii; Yoichiro Yoshida; Yasushi Yamauchi; Naoya Aisu; Daibo Kojima; Toshiyuki Mera; Daisuke Kato; Toshihiro Tanaka; Keiko Naito; Kosei Yasumoto; Takashi Kamigaki; Shigenori Goto; Yoshihiro Hamada; Satoshi Nimura; Shohta Kodama; Suguru Hasegawa
Journal:  Anticancer Res       Date:  2017-07       Impact factor: 2.480

2.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

Review 3.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

4.  A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; J T Vetto; C A Seipp; C Simpson
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

5.  Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy.

Authors:  Atsutaka Noguchi; Toru Kaneko; Keiko Naitoh; Masashi Saito; Kazuro Iwai; Ryuji Maekawa; Takashi Kamigaki; Shigenori Goto
Journal:  Int Immunopharmacol       Date:  2013-11-21       Impact factor: 4.932

Review 6.  Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.

Authors:  Sanna Iivanainen; Jussi P Koivunen
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.